Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aeterna Zentaris stock

Own Aeterna Zentaris stock in just a few minutes.

Aeterna Zentaris Inc is a biotechnology business based in the US. Aeterna Zentaris shares (AEZS) are listed on the NASDAQ and all prices are listed in US Dollars. Aeterna Zentaris employs 12 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Aeterna Zentaris

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AEZS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aeterna Zentaris share price

Use our graph to track the performance of AEZS stocks over time.

Aeterna Zentaris shares at a glance

Information last updated 2021-04-30.
52-week range$0.29 - $2.27
50-day moving average $1.11
200-day moving average $0.79
Wall St. target price$4.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.75

Buy Aeterna Zentaris shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aeterna Zentaris stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aeterna Zentaris financials

Revenue TTM $3.7 million
Gross profit TTM $1.3 million
Return on assets TTM -12.94%
Return on equity TTM -95.24%
Profit margin -140.14%
Book value $0.21
Market capitalisation $132.1 million

TTM: trailing 12 months

Shorting Aeterna Zentaris shares

There are currently 6.1 million Aeterna Zentaris shares held short by investors – that's known as Aeterna Zentaris's "short interest". This figure is 20.6% down from 7.7 million last month.

There are a few different ways that this level of interest in shorting Aeterna Zentaris shares can be evaluated.

Aeterna Zentaris's "short interest ratio" (SIR)

Aeterna Zentaris's "short interest ratio" (SIR) is the quantity of Aeterna Zentaris shares currently shorted divided by the average quantity of Aeterna Zentaris shares traded daily (recently around 11.1 million). Aeterna Zentaris's SIR currently stands at 0.55. In other words for every 100,000 Aeterna Zentaris shares traded daily on the market, roughly 550 shares are currently held short.

However Aeterna Zentaris's short interest can also be evaluated against the total number of Aeterna Zentaris shares, or, against the total number of tradable Aeterna Zentaris shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aeterna Zentaris's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Aeterna Zentaris shares in existence, roughly 50 shares are currently held short) or 0.0506% of the tradable shares (for every 100,000 tradable Aeterna Zentaris shares, roughly 51 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aeterna Zentaris.

Find out more about how you can short Aeterna Zentaris stock.

Aeterna Zentaris share dividends

We're not expecting Aeterna Zentaris to pay a dividend over the next 12 months.

Have Aeterna Zentaris's shares ever split?

Aeterna Zentaris's shares were split on a 1:100 basis on 19 November 2015. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aeterna Zentaris shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Aeterna Zentaris shares which in turn could have impacted Aeterna Zentaris's share price.

Aeterna Zentaris share price volatility

Over the last 12 months, Aeterna Zentaris's shares have ranged in value from as little as $0.29 up to $2.27. A popular way to gauge a stock's volatility is its "beta".

AEZS.US volatility(beta: 2.34)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeterna Zentaris's is 2.3373. This would suggest that Aeterna Zentaris's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aeterna Zentaris overview

Aeterna Zentaris Inc. , a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site